PDCL2: A Protein Involved in Disease and New Treatments (G132954)

Target Name: PDCL2

NCBI ID: G132954

PDCL2

Other Name(s): GCPHLP | PDCL2_HUMAN | phosducin like 2 | Phosducin-like protein 2 | Phosducin like 2

PDCL2: A Protein Involved in Disease and New Treatments

PDCL2 (Protamineuronucleotide-conjugated dextrinylated phosphatidylcholine) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. It is involved in the regulation of cellular signaling pathways, including the messenger RNA (mRNA) translation process . PDCL2 has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, PDCL2 has become a focus of interest for researchers studying the biology of disease and the development of new treatments.

PDCL2 is a member of the phosphatidylcholine (PC) family, which is a well-known protein that is involved in the formation of the cell membrane. PC is a major component of cell membranes and is responsible for maintaining the structural integrity and electrical properties of the membrane. PDCL2 is characterized by its ability to conjugate with aprotidine (dTMP) via a disulfide bond, which allows it to form a covalent complex with the protein known as protamineuronucleotide (pim) and form PDCL2-pim complexes. These complexes have been shown to play a role in regulating the translation of mRNAs into the cytoplasm, as well as in the regulation of various cellular processes, including cell signaling pathways.

PDCL2 has been shown to play a role in the regulation of mRNA translation by affecting the stability and localization of mRNAs in the cytoplasm. In addition, PDCL2 has been shown to interact with various cellular signaling proteins, including the transcription factor, RNA polymerase II ( RNA-P2), and the protein known as HIF1伪. These interactions have been shown to play a role in the regulation of various cellular processes, including cell growth, metabolism, and stress responses.

PDCL2 has also been shown to be involved in the development and progression of various diseases, including cancer. For example, PDCL2 has been shown to be involved in the regulation of the growth and survival of cancer cells. In addition, PDCL2 has been shown to play a role in the regulation of cellular signaling pathways that are involved in the development of cancer, including the regulation of cell proliferation and the regulation of apoptosis (programmed cell death).

As a result of its involvement in the regulation of cellular signaling pathways, PDCL2 has become a focus of interest for researchers studying the biology of disease and the development of new treatments. For example, researchers have been shown to be interested in using PDCL2 as a drug target or biomarker for the treatment of various diseases, including cancer. In addition, researchers have been shown to be interested in studying the regulation of PDCL2 by various cellular signaling pathways in order to gain a better understanding of its role in the development and progression of disease.

In conclusion, PDCL2 is a protein that is involved in the regulation of various cellular signaling pathways and has been shown to play a role in the development and progression of various diseases, including cancer. As a result, PDCL2 has become a focus of interest for researchers studying the biology of disease and the development of new treatments. Further research is needed to fully understand the role of PDCL2 in the regulation of cellular signaling pathways and its potential as a drug target or biomarker.

Protein Name: Phosducin Like 2

The "PDCL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDCL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets